Nephrotic Syndrome - Pipeline Review, H2 2017

  • ID: 4423501
  • Report
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Asahi Kasei Pharma Corp
  • Bristol-Myers Squibb Co
  • Orbis Biosciences Inc
  • Pfizer Inc
  • Retrophin Inc
  • MORE
Nephrotic Syndrome - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2017, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape.

Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema), foamy urine and weight gain due to excess fluid retention. Risk factors include diabetes, lupus, amyloidosis, HIV, hepatitis B, hepatitis C, malaria, certain medications (non-steroidal anti-inflammatory drugs and drugs used to fight infections).

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Asahi Kasei Pharma Corp
  • Bristol-Myers Squibb Co
  • Orbis Biosciences Inc
  • Pfizer Inc
  • Retrophin Inc
  • MORE
Introduction

Nephrotic Syndrome - Overview

Nephrotic Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Nephrotic Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nephrotic Syndrome - Companies Involved in Therapeutics Development

AbbVie Inc

Asahi Kasei Pharma Corp

Aurinia Pharmaceuticals Inc

Bristol-Myers Squibb Co

Orbis Biosciences Inc

Pfizer Inc

Retrophin Inc

Sarfez Pharmaceuticals Inc

Nephrotic Syndrome - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atrasentan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cosyntropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Inhibit Complement C3 for Nephrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mizoribine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06730512 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prednisone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-20104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voclosporin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nephrotic Syndrome - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Nephrotic Syndrome, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Nephrotic Syndrome - Pipeline by AbbVie Inc, H2 2017

Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, H2 2017

Nephrotic Syndrome - Pipeline by Aurinia Pharmaceuticals Inc, H2 2017

Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Co, H2 2017

Nephrotic Syndrome - Pipeline by Orbis Biosciences Inc, H2 2017

Nephrotic Syndrome - Pipeline by Pfizer Inc, H2 2017

Nephrotic Syndrome - Pipeline by Retrophin Inc, H2 2017

Nephrotic Syndrome - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017

Nephrotic Syndrome - Dormant Projects, H2 2017

List of Figures

Number of Products under Development for Nephrotic Syndrome, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Asahi Kasei Pharma Corp
  • Aurinia Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Orbis Biosciences Inc
  • Pfizer Inc
  • Retrophin Inc
  • Sarfez Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll